The Alzheimer’s Association International Conference (AAIC) Toronto July 27-31 2025

AAIC Session July 30, 2025 “Network alterations and aberrant neuronal activity in Alzheimer’s disease: novel targets to understand and influence disease progression” Our presentation within this scientific session focused on AD biomarker findings in AgeneBio’s HOPE4MCI clinical trial. AgeneBio’s presentation also announced the development of novel GABA alpha5 PAMS to optimally target the condition of…